Lacy Almeida: How to Safely Prescribe Antidepressants With Bleeding-Risk Medications?
Lacy Almeida, Advanced Practice Psychiatric Nurse at Lavender, shared a post on LinkedIn:
”Psychiatry Simplified:
How to prescribe an antidepressant when the patient is already on an anticoagulant, antiplatelet, or NSAID.
SSRIs and SNRIs block platelet serotonin uptake and impair aggregation. This effect adds to any antithrombotic. The absolute risk increase is modest, and a real indication is rarely a reason to withhold treatment. The job is to select and monitor deliberately.
Step 1: Assess baseline risk. Look for age, prior GI or intracranial bleed, active ulcer disease, alcohol use, and thrombocytopenia. Dual antiplatelet therapy and anticoagulant plus antiplatelet regimens carry the highest risk. The NSAID combination is the most dangerous of all.
Step 2: Pick the lowest-risk agent. Bupropion and mirtazapine have minimal serotonin transporter affinity. They are preferred when bleeding risk is high. If an SSRI is needed, sertraline is a reasonable choice. Citalopram and escitalopram have clean CYP profiles, but be mindful of QTc prolongation risk.
Step 3: Avoid strong CYP inhibitors with warfarin and DOACs. Fluoxetine and fluvoxamine carry the highest interaction risk. They are best avoided in anticoagulated patients.
Step 4: Add gastroprotection. Co-prescribe a PPI when an SSRI is combined with an NSAID or with dual antithrombotic therapy. Do the same for any patients with a prior GI bleed. Minimize NSAIDs where you can.
Step 5: Monitor and coordinate. Bleeding risk peaks in the first 30 days and persists up to 6 months. With warfarin, check INR more often around any start, change, or stop. DOACs have no routine level to follow, so monitor them clinically.
Counsel every patient on melena, easy bruising, and prolonged bleeding. Coordinate with whoever manages the anticoagulation.
Match the drug to the whole patient.
Do not match it to the diagnosis alone.”
Stay updated with Hemostasis Today.
-
Oct 12, 2026, 17:15Cedric Hermans: Identifying and Diagnosing Hemophilia Carriers and Affected Females
-
Oct 12, 2026, 17:01Bianca Rocca: Evaluating Factor XI Inhibition Lessons from LIBREXIA-ACS
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026
-
Oct 12, 2026, 10:36PAI-1 Inhibition as a New Strategy for Enhancing Fibrinolysis and Clot Resolution